Description
Retatrutide is a synthetic peptide research compound characterized as a triple agonist at the GIP, GLP-1, and glucagon receptors. It has been studied in preclinical research as a tool compound for isolating multi-receptor incretin and glucagon signaling endpoints in metabolic experimental designs.
Retatrutide has been examined in preclinical in vitro and rodent model studies of glucose homeostasis, energy expenditure, lipid metabolism, and triple receptor signaling dynamics. Its combined receptor activity supports comparative mechanistic studies of incretin and glucagon biology in cell-based and rodent research.
Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.
Reviews
There are no reviews yet.